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Background: Elevated vascular endothelial growth factor (VEGF) was associated with poor prognosis in leptomeningeal
carcinomatosis and anti-angiogenic therapy was found to prolong the survival of mice in preclinical studies. This
prospective pilot study investigated the efficacy of anti-VEGF therapy plus chemotherapy in patients with leptomeningeal
carcinomatosis originating from breast cancer.
Methods: Eligible patients were scheduled to receive bevacizumab combined with etoposide and cisplatin (BEEP)
every 3 weeks for a maximum of 6 cycles or until unacceptable toxicity. The primary objective was the central nervous
system (CNS)-specific response rate, which was defined as disappearance of cancer cells in the cerebrospinal fluid (CSF)
and an improved or stabilized neurologic status. The impact of VEGF inhibition on etoposide penetration into the CSF
was analyzed.
Results: Eight patients were enrolled. The CNS-specific response rate was 60% in 5 evaluable patients. According to
intent-to-treat analysis, the median overall survival of the eight patients was 4.7 months (95% confidence interval, CI,
0.3–9.0) and the neurologic progression-free survival was 4.7 months (95% CI 0–10.5). The most common grade 3/4
adverse events were neutropenia (23.1%), leukopenia (23.1%), and hyponatremia (23.1%). The etoposide concentrations
in the CSF were much lower than those in plasma, and bevacizumab did not increase etoposide delivery to the CSF.
Conclusions: BEEP exhibited promising efficacy in breast cancer patients with leptomeningeal carcinomatosis.
Additional studies are warranted to verify its efficacy and clarify the role of anti-angiogenic therapy in this disease.
Trial registration: ClinicalTrials.gov identifying number NCT01281696.
Keywords: Leptomeningeal carcinomatosis, Bevacizumab, Vascular endothelial growth factor (VEGF), Anti-angiogenic
therapy, Anti-VEGF therapyBackground
Leptomeningeal carcinomatosis results from the spread
of cancer cells to the leptomeninges and dissemination
within the cerebrospinal fluid (CSF). It has become in-
creasingly common because of the prolonged survival of
cancer patients and improvements of diagnostic methods.
Approximately 4% − 15% of patients with solid cancers* Correspondence: yslu@ntu.edu.tw
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cers, lung cancers, and melanoma are the most common
origins. The treatments include intra-CSF and systemic
chemotherapy, irradiation, and surgery of bulky metas-
tases. Despite the administration of aggressive treatments,
the prognosis is poor, with the median overall survival
(OS) ranging from 8 to 16 weeks [1,2].
Recent studies have shown that vascular endothelial
growth factor (VEGF) levels in the CSF were significantly
higher in patients with leptomeningeal carcinomatosis
and correlated with a poor prognosis [3-5]. Reijneveld
et al. also found that inhibition of angiogenesis prolonged
the survival of mice with leptomeningeal carcinomatosisis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in this disease.
Bevacizumab is a recombinant, humanized monoclonal
antibody directed against VEGF. It has exhibited efficacy
in metastatic breast cancer, colorectal cancer, non-small-
cell lung cancer (NSCLC), and glioblastoma multiforme.
Our previous study of bevacizumab combined with etopo-
side and cisplatin (BEEP) demonstrated significant activity
for brain metastasis of breast cancer that progressed
after whole brain radiation therapy [7]. This pilot study
examined the efficacy of BEEP in breast cancer patients
with leptomeningeal carcinomatosis. Translational re-
search was performed to evaluate the effects of anti-
VEGF therapy on drug delivery to the CSF.
Methods
Study design
This prospective, multicenter pilot study was conducted to
evaluate the efficacy and safety of BEEP in patients with
leptomeningeal carcinomatosis originating from breast
cancer. The study was performed at 3 centers in Taiwan
from November 2010 to March 2013. The protocol was
approved by the research ethics committees of all of the
participating centers (National Taiwan University Hospital
Research Ethics Committee and Institutional Review
Board of Taichung Veterans General Hospital). This trial is
registered on ClinicalTrials.gov and has the identification
number NCT01281696.
Eligibility criteria
Patients who had leptomeningeal carcinomatosis ori-
ginating from breast cancer, based on positive CSF cy-
tology findings, were eligible to participate in this study.
Additional inclusion criteria were an age of 18 to
75 years and adequate organ functions and bone mar-
row reserve.
The major exclusion criteria were prior VEGF-targeted
therapy; a history of thrombotic or hemorrhagic dis-
orders; severe nonhealing wounds, ulcers, or bone frac-
tures; regular use of medication that increases bleeding
tendency.
Concurrent intrathecal treatment with methotrexate
was permitted during the study period. Patients were re-
quired to sign an informed consent form before being
enrolled in the study.
Treatment administration
Patients were scheduled to receive BEEP (15 mg/kg of
bevacizumab on Day 1; etoposide at 70 mg/m2/d from
Day 2 to Day 4; and cisplatin at 70 mg/m2/d on Day 2)
every 3 weeks for a maximum of 6 cycles or until a level
of unacceptable toxicity was reached. The use of pro-
phylactic G-CSF (granulocyte colony-stimulating factor)
was allowed.In the first cycle, some modifications of the treatment
schedule for the translational research were introduced.
Etoposide was administered from Day 1 to Day 3, and
bevacizumab was administered 6 hours after etoposide
infusion was completed on Day 1.
Cerebrospinal fluid concentration of etoposide
Patients who had an Ommaya reservoir were subjected
to translational research to assess the effects of anti-
VEGF treatment on the delivery of etoposide to the CSF.
The temporal changes in the etoposide concentration in
the CSF and plasma were determined using ultrahigh-
performance liquid chromatography with tandem mass
spectrometry, as previously described [8].
Efficacy assessments
Clinical evaluations, including physical, neurological,
and CSF cytology examinations, were performed at the
baseline and during the study. Tumor-associated neuro-
logical signs and symptoms were assessed based on the
criteria used by Lin et al. [9]. Cytologic negative conver-
sion was defined as the absence of malignant cells in the
CSF 2 times in succession. A CNS-specific response was
defined as a negative conversion according to the CSF
cytology results and a stable or improved neurological
status. Patients whose CSF cytology results were persis-
tently positive or positive after only one negative cytology
result was obtained were considered nonresponders. Neu-
rologic progression was defined as the observation of
positive cytology results after confirmation of a negative
conversion, or evidence of leptomeningeal disease pro-
gression upon neurological examination [10,11]. All pa-
tients were followed until death.
Safety assessments
Adverse events (AE) were assessed and graded according
to NCI CTCAE v3.0 (National Cancer Institute Common
Terminology Criteria for Adverse Events). The patients
were followed for safety until at least 30 days after discon-
tinuation of the study drug. Severe AEs were defined ac-
cording to International Conference on Harmonization
Good Clinical Practice guidelines. The safety profile was
evaluated by recording the incidence and severity of AEs.
Study objectives
The primary end point of the study was the CNS-
specific response rate. Secondary end points included
neurologic progression-free survival (PFS) and OS. Fur-
thermore, the study evaluated the impact of VEGF in-
hibition on etoposide penetration into the CSF.
Statistics
OS was defined as the time from the initiation of the
study medications until death from any cause or the date
Table 2 Numbers of major adverse events of the
indicated grade (total 26 cycles)
Grade 1/2 Grade 3/4 All grades




9 34.6 6 23.1 15 57.7
Lymphocyte
count decreased
9 34.6 6 23.1 15 57.7
Anemia 13 50.0 0 0.0 13 50.0
Platelet count
decreased
10 38.5 1 3.8 11 42.3
Non-hematological
Hypertension 14 53.8 0 0.0 14 53.8
ALT/AST
increased
6 23.1 2 7.7 8 30.8
Headache 8 30.8 0 0.0 8 30.8
Hyponatremia 1 3.8 6 23.1 7 26.9
Proteinuria 7 26.9 0 0.0 7 26.9
Table 1 Patient characteristic at baseline
Patients (N = 8)
Age, median (range), years 55 (30–65)
Histology, N (%)
Invasive ductal carcinoma 6 (75%)
Invasive lobular carcinoma 1 (13%)
Unknown 1 (13%)
Hormone receptor status, N (%)
ER+ and PR+ 3 (38%)
ER- and PR- 5 (63%)
HER2 expression, N (%)
IHC 0-2+ and/or FISH- 3 (38%)
IHC 2+ and FISH+, IHC3+ 2 (25%)
Triple negative, N (%)
Yes 3 (38%)
No 5 (63%)









Coexisting brain parenchymal metastasis, N (%)
Yes 7 (88%)
No 1 (13%)
Prior therapy for CNS metastasis, N (%)
Surgery 2 (25%)
Radiotherapy 4 (50%)
Numbers of metastatic sites, N (%)










Systemic disease not under control, N (%) 5 (63%)
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defined as the time from the initiation of the study
medications until the earliest date of neurologic diseaseprogression or death from any cause. OS and PFS
estimates were obtained using Kaplan–Meier survival
curves. Continuous variables are reported as means and
ranges. Categorical variables are reported as frequencies
and percentages. All statistical evaluations were per-
formed using SPSS 15.0. A statistical difference was con-
sidered to be significant when P < .05.
Results
Patient characteristics
A total of 8 patients were enrolled in the study, and their
baseline clinical characteristics are listed in Table 1. The
median age was 55 years (range, 30–65 y) and the me-
dian ECOG (Eastern Cooperative Oncology Group) per-
formance status was 2.5 (range, 2–3). Three patients
(38%) had received hormone therapy, 2 patients (25%)
had received HER2-targeted therapy, and 8 patients
(100%) had received chemotherapy for their primary dis-
ease; furthermore, 2 patients (25%) had undergone sur-
gery, 4 patients (50%) had undergone radiotherapy, and
6 patients (75%) had received intrathecal chemotherapy
for CNS metastases. Five patients (63%) exhibited lepto-
meningeal metastasis according to MRI examination.
Systemic disease outside the central nervous system
(CNS) was not under control at the time of leptomenin-
geal carcinomatosis diagnosis in 5 patients (63%).
Treatment administration
The mean number of cycles administered was 3.3
(median, 3.0). Only 2 of 8 patients (25%) completed the
planned 6 cycles of treatments. The reasons that 6 pa-
tients did not complete the study are listed as follows:
one patient (13%) exhibited both CNS and extra-CNS
Figure 1 Efficacy results: Overall Survival (OS) and neurologic
progression free survival (PFS).
Table 3 Clinical characteristics and outcomes of the patients






PFS (m) OS (m)
1 53 ILC Yes Improved Responder No PD 10.7 10.7
2 65 NA NA NA NA NA 0.7 0.7*
3 35 IDC No Improved Non-responder No PD 7.6 7.6
4 63 IDC Yes Improved Responder No PD 9.0 9.0
5 63 IDC Yes Improved Responder Liver PD 4.7 4.7
6 30 IDC No Progressed Progression Breast PD 2.9 2.9
7 49 IDC NA NA NA NA 0.7 0.7
8 56 IDC NA NA NA NA 1.6 1.6
*Censored.
Abbreviations: ILC invasive lobular carcinoma, NA not available, IDC invasive ductal carcinoma, PD progressive disease, Bev bevacizumab administration,
PFS progression free survival, OS overall survival.
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extra-CNS disease progression; one patient (13%) exhi-
bited no CSF cytologic response; and 3 patients (38%)
withdrew from the study. Six patients concurrently re-
ceived intrathecal methotrexate therapy. The treatment
course of each patient is shown in the Additional file 1.
Safety
The AEs are listed in Table 2. The most common grade
3/4 AEs were neutropenia (23.1%), leukopenia (23.1%),
and hyponatremia (23.1%). Nonhematologic toxicity was
generally modest. All AEs resolved to grade 1 or lower.
Efficacy
The patient characteristics and their outcomes are listed
in the Table 3. Because 3 patients withdrew from the
study before undergoing follow-up CSF studies and
neurologic assessments, the CNS-specific response was
evaluable in 5 patients. Three patients (60%) were re-
sponsive, exhibiting the clearance of malignant cells in
successive CSF studies, and 2 of them completed the
planned treatment courses. One patient was considered
nonresponsive because positive cytology results were
observed after a single negative cytology result was ob-
tained, and one patient’s CSF cytology results were per-
sistently positive. Clinically, 3 patients (60%) improved
neurologically without evidence of systemic progression;
one patient (20%) was neurologically stable but pro-
gressed systemically; and one patient (20%) exhibited
both neurologic and systemic progression.
The 8 patients were subjected to a survival analysis
according to the intent-to-treat analysis. The median OS
was 4.7 months (95% CI 0.3–9.0; Figure 1). The re-
sponders of CSF cytology had a trend toward longer me-
dian overall survival (9.0 vs 2.9 months, P = 0.076). The
OS of the 3 responders was 10.7, 9.0, and 4.7 months re-
spectively. The neurologic PFS was 4.7 months (95% CI
0–10.5; Figure 1).Cerebrospinal fluid concentration of etoposide
Four patients were subjected to serial measurements of
etoposide concentrations in the CSF and plasma before
and after bevacizumab administration. A plot of the
individual ratio of the etoposide concentration in the
CSF to that in the plasma versus time is shown in
Figure 2A. We observed that bevacizumab administered
24 hours prior to the administration of cytotoxic drugs
exerted no significant effects on etoposide penetration
into the CSF (Figure 2B, P = .167, .680, .754, at 1 h, 2 h,
and 6 h, respectively).
Discussion
Several retrospective studies and case reports have demon-
strated the feasibility of using systemic therapies, including
capecitabine, lapatinib, gefitinib, erlotinib, and bevacizu-
mab therapies, in treating leptomeningeal carcinomatosis
Figure 2 The effects of bevacizumab administration on the temporal
changes of CSF to plasma ratio of etoposide concentration.
(A) Individual CSF/ Plasma ratio of etoposide concentration versus
time plot. (B) Overall CSF/Plasma ratio of etoposide concentration
versus time plot.
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have been conducted [18-22] (Table 4). This is partly be-
cause of the difficulties in conducting a large trial
among patients with extremely poor prognoses, for
whom treatment may be discontinued early, precluding
a full assessment of the agents that exhibit potential
activity in treating this disease.Table 4 Prospective clinical trials of systemic therapy for lept
Drugs Study Primary tumor
Methotrexate [19] Breast, lung
Temozolomide [22] Breast, lung, melanoma
Topotecan and ifosfamide [20] Breast, lung
Patupilone [21] Breast
Bevacizumab [23] Breast, lung, melanoma
Bevacizumab, etoposide
and cisplatin
Wu et al., 2015 BreastAccording to our thorough review of research, this is
the first prospective pilot study to report on the efficacy
of anti-VEGF therapy plus chemotherapy in leptome-
ningeal carcinomatosis. Specifically, the CNS-specific re-
sponse rate was 60% and the median OS was 4.7 months
(95% CI 0.3–9.0). Groves et al. [23] reported that admi-
nistration of bevacizumab alone yielded a 13% CSF re-
sponse and a median OS of 14 weeks. Because of the
heterogeneity of the enrolled patients and differences in
response criteria among studies, comparing the efficacy
of various systemic treatments is difficult (Table 4). In
addition, the ability to make statistically sound conclu-
sions was limited by the small sample size of our study.
Because this patient population is seldom included in
clinical trials, any treatment with evidence of response
warrants further investigation.
Among the 8 patients enrolled in this study, 3 patients
dropped out during the early phase of the trial due to
patients’ refusal of continued treatments. Only 5 patients
underwent follow-up CSF studies and neurologic assess-
ments, and were evaluable for the CNS-specific re-
sponse. In addition to excluding the 3 dropouts in the
final analysis, the response rates could also be estimated
by assuming that the 3 dropped patients were non-
responders, that is, 3/8 (38%). In this way, it underesti-
mated the true response rate and could be considered as
a low bound of the estimated response rate based on the
data of this study. Similarly, the PFS could also be
analyzed in two ways by including (1) all 8 patients, and
(2) only the 5 patients who completed the response
evaluation. The former included the 3 dropped patients
who did not complete the response evaluation, and thus
it also underestimated the effect of the proposed treat-
ment on PFS (4.7 months versus 7.6 months) and could
be considered as a low bound of the estimated effect of
the proposed treatment on PFS based on the data of
this study.
Intrathecal methotrexate has been used for a long time,
but its value is questioned, with median survival of aboutomeningeal carcinomatosis
Phase N Efficacy
I 13 0% cytologic and clinical response.
II 19 11% cytologic or radiological response;
TTP 28 days.
II 7 28% radiological response; TTP 51 days;
OS 218 days.
II 5 0% cytologic and radiologic response;
3 months CNS PFS rate, 20%.
II 15 (Ongoing) 7% best protocol responses; 13% CSF
response; PFS 6 weeks; mOS 14 weeks.
II 8 60% CNS-specific response rate; OS 4.7 mos.
Wu et al. BMC Cancer  (2015) 15:299 Page 6 of 77–16 weeks in previous reports (7 weeks, Fizazi et al.;
11 weeks, Glantz et al.; 16 weeks, Rudnicka et al. and
Grossman et al.) [11,24-26]. The median overall survival
in our study was 4.7 months, which seems slightly better
than intrathecal methotrexate treatment in previous se-
rials. Although the efficacy of bevacizumab-based therapy
might be confounded by the concurrent intrathecal me-
thotrexate therapy administered in this study, the observa-
tion that one patient was responsive to BEEP rechallenge
while disease progressed under maintenance intrathecal
methotrexate therapy provides evidence that BEEP can
benefit leptomeningeal carcinomatosis patients (Table 3,
Patient 1).
Increasing evidence suggests that abnormal tumor vas-
culature can hinder effective cancer therapy; further-
more, VEGF inhibition can transiently normalize tumor
vasculature and improve tumor perfusion as well as the
delivery of subsequent chemotherapy [27-29]. In the
study conducted by Dickson et al., the penetration of
chemotherapy was improved when it was administered 1
to 3 days after bevacizumab administration in the neuro-
blastoma xenograft model [29]. Although Van der Veldt
et al. observed that bevacizumab reduced perfusion and
the uptake of trace amounts of [11C] docetaxel in
NSCLC tissues within 5 hours to at least 4 days, the ef-
fects of bevacizumab on microdoses of drug delivery in
tumors may not hold true for pharmacological drug con-
centrations [30].
In the present study, cytotoxic drugs were adminis-
tered 24 hours after the administration of bevacizumab
to enhance efficacy based on the normalization theory
[29-31]. We observed that anti-VEGF therapy exerted
no significant effects on the penetration of etoposide
into the CSF. Additional studies are required to clarify
whether different schedules for treatments in which bev-
acizumab is combined with cytotoxic agents increase
drug penetration into the CSF and improve the treat-
ment efficacy.
Conclusions
BEEP regimen exhibited promising efficacy in breast
cancer patients with leptomeningeal carcinomatosis. Ad-
ditional studies are warranted to verify the efficacy of the
regimen and clarify the role of bevacizumab in this disease.
Additional file
Additional file 1: The treatment course of each patient.
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